Announcement • Jul 18
NanoRepro AG to Report Fiscal Year 2025 Results on Jul 30, 2026 NanoRepro AG announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Jul 30, 2026 New Risk • May 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€19.8m market cap, or US$23.0m). Breakeven Date Change • Apr 26
Forecast to breakeven in 2027 The 2 analysts covering NanoRepro expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €500.0k in 2027. Average annual earnings growth of 89% is required to achieve expected profit on schedule. Announcement • Feb 28
NanoRepro AG announced that it expects to receive €1.935 million in funding NanoRepro AG announced a private placement of 1,290,000 common shares at a price of €1.50 per share for gross proceeds of €1,935,000 on February 27, 2026. The transaction has been approved by the board of directors of the company. New Risk • Jul 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (€19.8m market cap, or US$23.2m). Announcement • Jul 22
NanoRepro AG, Annual General Meeting, Aug 26, 2025 NanoRepro AG, Annual General Meeting, Aug 26, 2025, at 14:00 W. Europe Standard Time. Reported Earnings • Jul 21
Full year 2024 earnings released Full year 2024 results: Revenue: €4.69m (up 47% from FY 2023). Net loss: €2.05m (loss narrowed 56% from FY 2023). Announcement • May 08
NanoRepro AG to Report Fiscal Year 2024 Results on Jun 30, 2025 NanoRepro AG announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Jun 30, 2025 New Risk • May 04
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Revenue is less than US$5m (€3.6m revenue, or US$4.0m). Market cap is less than US$100m (€17.9m market cap, or US$20.2m). Reported Earnings • Oct 18
First half 2024 earnings released: €0.092 loss per share (vs €0.21 loss in 1H 2023) First half 2024 results: €0.092 loss per share (improved from €0.21 loss in 1H 2023). Revenue: €1.77m (up 27% from 1H 2023). Net loss: €1.17m (loss narrowed 56% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 11
Full year 2023 earnings released Full year 2023 results: Revenue: €3.25m (down 92% from FY 2022). Net loss: €4.69m (loss widened 26% from FY 2022). New Risk • May 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€22.0m market cap, or US$23.9m). Announcement • Feb 01
NanoRepro AG, Annual General Meeting, Jul 25, 2024 NanoRepro AG, Annual General Meeting, Jul 25, 2024. Announcement • Jan 30
NanoRepro AG SHS to Be Deleted from OTC Equity NanoRepro AG SHS (Germany Federal Republic) will be deleted from OTC Equity effective January 30, 2024, due to Inactive Security. Reported Earnings • Nov 06
First half 2023 earnings released: €0.21 loss per share (vs €0.016 profit in 1H 2022) First half 2023 results: €0.21 loss per share (down from €0.016 profit in 1H 2022). Revenue: €1.39m (down 95% from 1H 2022). Net loss: €2.65m (down €2.86m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Buying Opportunity • Sep 25
Now 20% undervalued Over the last 90 days, the stock is up 21%. The fair value is estimated to be €3.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 49% over the last 3 years. Meanwhile, the company became loss making. Announcement • Aug 18
NanoRepro AG to Report First Half, 2023 Results on Sep 26, 2023 NanoRepro AG announced that they will report first half, 2023 results on Sep 26, 2023 New Risk • Aug 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€31.2m market cap, or US$34.1m). Buying Opportunity • Aug 02
Now 21% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be €2.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 49% over the last 3 years. Meanwhile, the company became loss making. Buying Opportunity • Jun 21
Now 21% undervalued Over the last 90 days, the stock is up 13%. The fair value is estimated to be €2.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 49% over the last 3 years. Meanwhile, the company became loss making. Upcoming Dividend • Jun 09
Upcoming dividend of €0.15 per share at 6.2% yield Eligible shareholders must have bought the stock before 16 June 2023. Payment date: 20 June 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 6.2%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%). Announcement • Jan 24
NanoRepro AG, Annual General Meeting, Jun 16, 2023 NanoRepro AG, Annual General Meeting, Jun 16, 2023. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 16% share price gain to €2.69, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 27x in the Medical Equipment industry in Germany. Total returns to shareholders of 384% over the past three years. Reported Earnings • Sep 29
First half 2022 earnings released: EPS: €0 (vs €2.01 in 1H 2021) First half 2022 results: EPS: €0 (down from €2.01 in 1H 2021). Revenue: €26.1m (down 78% from 1H 2021). Net income: €204.5k (down 99% from 1H 2021). Profit margin: 0.8% (down from 22% in 1H 2021). The decrease in margin was driven by lower revenue. Announcement • Sep 21
NanoRepro AG to Report First Half, 2022 Results on Sep 27, 2022 NanoRepro AG announced that they will report first half, 2022 results on Sep 27, 2022 Reported Earnings • Jun 17
Full year 2021 earnings released Full year 2021 results: Revenue: €162.8m (up €145.9m from FY 2020). Net income: €29.7m (up €28.0m from FY 2020). Profit margin: 18% (up from 10.0% in FY 2020). The increase in margin was driven by higher revenue. Announcement • Feb 17
NanoRepro AG, Annual General Meeting, Apr 29, 2022 NanoRepro AG, Annual General Meeting, Apr 29, 2022. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €4.85, the stock trades at a trailing P/E ratio of 2.3x. Average trailing P/E is 26x in the Medical Equipment industry in Germany. Total returns to shareholders of 345% over the past three years. Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €5.51, the stock trades at a trailing P/E ratio of 2.6x. Average trailing P/E is 26x in the Medical Equipment industry in Germany. Total returns to shareholders of 388% over the past three years. Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €7.95, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 26x in the Medical Equipment industry in Germany. Total returns to shareholders of 718% over the past three years. Valuation Update With 7 Day Price Move • Nov 16
Investor sentiment improved over the past week After last week's 18% share price gain to €9.94, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 29x in the Medical Equipment industry in Germany. Total returns to shareholders of 829% over the past three years. Valuation Update With 7 Day Price Move • Oct 21
Investor sentiment improved over the past week After last week's 19% share price gain to €8.75, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 640% over the past three years. Valuation Update With 7 Day Price Move • Oct 07
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €7.57, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 480% over the past three years. Reported Earnings • Sep 26
First half 2021 earnings released: EPS €2.01 (vs €0.035 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €120.0m (up €117.8m from 1H 2020). Net income: €25.9m (up €25.6m from 1H 2020). Profit margin: 22% (up from 15% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 152% per year but the company’s share price has only increased by 82% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €8.60, the stock trades at a trailing P/E ratio of 47.3x. Average trailing P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 508% over the past three years. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment improved over the past week After last week's 16% share price gain to €6.50, the stock trades at a trailing P/E ratio of 35.8x. Average trailing P/E is 35x in the Medical Equipment industry in Germany. Total returns to shareholders of 360% over the past three years. Valuation Update With 7 Day Price Move • May 29
Investor sentiment deteriorated over the past week After last week's 20% share price decline to €6.62, the stock trades at a trailing P/E ratio of 36.4x. Average trailing P/E is 35x in the Medical Equipment industry in Germany. Total returns to shareholders of 396% over the past three years. Is New 90 Day High Low • Feb 24
New 90-day high: €9.40 The company is up 181% from its price of €3.34 on 26 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 21% over the same period. Is New 90 Day High Low • Feb 04
New 90-day high: €4.38 The company is up 18% from its price of €3.70 on 06 November 2020. The German market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Medical Equipment industry, which is up 20% over the same period. Is New 90 Day High Low • Oct 12
New 90-day high: €1.92 The company is up 75% from its price of €1.10 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. Is New 90 Day High Low • Sep 23
New 90-day high: €1.76 The company is up 59% from its price of €1.11 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period.